MA51146B1 - Bicyclic substituted heterocyclic compounds used as prmt5 inhibitors - Google Patents
Bicyclic substituted heterocyclic compounds used as prmt5 inhibitorsInfo
- Publication number
- MA51146B1 MA51146B1 MA51146A MA51146A MA51146B1 MA 51146 B1 MA51146 B1 MA 51146B1 MA 51146 A MA51146 A MA 51146A MA 51146 A MA51146 A MA 51146A MA 51146 B1 MA51146 B1 MA 51146B1
- Authority
- MA
- Morocco
- Prior art keywords
- heterocyclic compounds
- substituted heterocyclic
- compounds used
- prmt5 inhibitors
- bicyclic substituted
- Prior art date
Links
- 101150097768 prmt5 gene Proteins 0.000 title abstract 3
- -1 Bicyclic substituted heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 4
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000002018 overexpression Effects 0.000 abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des composés hétérocycliques bicycliques substitués de formule (i), des sels pharmaceutiquement acceptables de ceux-ci et des compositions pharmaceutiques pour le traitement de maladies, de troubles ou d'états pathologiques associés à la surexpression de l'enzyme prmt5. L'invention concerne également des méthodes de traitement de maladies, de troubles ou d'états pathologiques associés à la surexpression de l'enzyme prmt5.Disclosed herein are substituted bicyclic heterocyclic compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions for the treatment of diseases, disorders, or disease states associated with overexpression of the enzyme prmt5. Also provided are methods of treating diseases, disorders, or disease states associated with overexpression of the enzyme prmt5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721044886 | 2017-12-13 | ||
| PCT/IB2018/060015 WO2019116302A1 (en) | 2017-12-13 | 2018-12-13 | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51146A MA51146A (en) | 2021-03-24 |
| MA51146B1 true MA51146B1 (en) | 2022-10-31 |
Family
ID=83995765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51146A MA51146B1 (en) | 2017-12-13 | 2018-12-13 | Bicyclic substituted heterocyclic compounds used as prmt5 inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA51146B1 (en) |
-
2018
- 2018-12-13 MA MA51146A patent/MA51146B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA51146A (en) | 2021-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43169B1 (en) | Heterocyclic compounds as pi3k-gamma inhibitors | |
| SA521421205B1 (en) | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer | |
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| MA47079A (en) | AMINO-TRIAZOLOPYIDINE COMPOUNDS AND THEIR USE TO TREAT CANCER | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| MA57825B1 (en) | SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATORS | |
| MA64509B1 (en) | HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS | |
| MA64121B1 (en) | HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS | |
| MA46229B1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| MA54133A (en) | AMINOPYRAZINE DIOL COMPOUNDS USED AS PI3K-Y INHIBITORS | |
| MA43979B1 (en) | 1h-indazole-3-carboxamide derivatives and similar compounds as d-factor inhibitors for the treatment of diseases characterized by aberrant activity of the complementary system, such as p.E. Immunological disorders | |
| MA44674A (en) | BROMODOMAIN INHIBITORS | |
| MA41179A (en) | PARG INHIBITOR COMPOUNDS | |
| EA200900152A1 (en) | PYRROLOTRIAZINKINASE INHIBITORS | |
| WO2019133770A3 (en) | Glycolate oxidase inhibitors for the treatment of disease | |
| MA49956B1 (en) | Pyrimidine compounds used as jak kinase inhibitors | |
| MA40955B1 (en) | 2-amino-6- (difluoromethyl) -5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| MA50013B1 (en) | BENZOAZEPINE ANALOGS AS BRUTON'S TYROSINE KINASE INHIBITORS | |
| EA202192900A1 (en) | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAYS | |
| NZ762437A (en) | Novel heterocyclic compounds as cdk8/19 inhibitors | |
| MA53372B1 (en) | Pyridopyrimidinenes as histamine h4 receptor inhibitors | |
| MA68743B1 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE ACTIVITY OF THE LPA RECIPIENT | |
| EA202190452A1 (en) | CDK8 / 19 INHIBITORS | |
| MX2022003873A (en) | Substituted 1, 6-naphthyridine inhibitors of cdk5. | |
| MA51146B1 (en) | Bicyclic substituted heterocyclic compounds used as prmt5 inhibitors |